Head

Garry Menzel joins GHO Capital as Operating Partner

Retrieved on: 
Tuesday, April 23, 2024
Diamond, Credit Suisse, Doctor of Philosophy, Goldman Sachs, Stanford University, University, DSM-IV codes, Partner, ADAP, M.B.A, Immunotherapy, Molecular biology, Patient, Operating partner, GHO, Clinical trial, Therapy, Health, Biotechnology, Head, Pharmaceutical industry

London, UK – 23 April 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Dr. Garry Menzel as Operating Partner.

Key Points: 
  • London, UK – 23 April 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Dr. Garry Menzel as Operating Partner.
  • As Operating Partner, Garry will leverage his extensive biotech industry experience in building innovative businesses to guide the GHO portfolio to deliver market leading services to the emerging biopharma space, as well as supporting GHO with deal origination across Europe and the US.
  • On behalf of the entire GHO team, we wish him a warm welcome.”
    Commenting on his new appointment, Garry Menzel, Operating Partner at GHO Capital, said: “Throughout my career, I have been committed to bringing forward the highest possible innovative standards for patients within the healthcare system whilst creating long-term investor value.
  • I am excited to support GHO Capital, as Europe’s leading healthcare specialist private equity firm, to pursue the same goal.

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

Retrieved on: 
Monday, April 22, 2024
Hope, Hearing loss, Tissue, Regeneron Pharmaceuticals, Gene silencing, Abstract, Gene editing, Cell, Genetics, Senior, Liver, Patient, Gene, Society, Antibody, Clinical trial, Head, Pharmaceutical industry

TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference in Baltimore, Maryland, from May 7 to 11, 2024. Data from 10 abstracts, including six oral presentations, provide insight on Regeneron’s approach to overcoming obstacles to clinical implementation of genetic medicines, from pre-dosing to delivery to long-term sustained expression. The company will also present updated data from the Phase 1/2 CHORD trial investigating DB-OTO in children with profound genetic hearing loss due to mutations of the otoferlin gene.

Key Points: 
  • Data from 10 abstracts, including six oral presentations, provide insight on Regeneron’s approach to overcoming obstacles to clinical implementation of genetic medicines, from pre-dosing to delivery to long-term sustained expression.
  • The company will also present updated data from the Phase 1/2 CHORD trial investigating DB-OTO in children with profound genetic hearing loss due to mutations of the otoferlin gene.
  • “Regeneron continues to advance methods to overcome these obstacles through our proprietary delivery approaches utilizing next-generation viral vectors, particularly specific retargeting antibodies and innovative payloads.
  • The ASGCT presentation will build on promising early results in the first patient,” said Aris Baras, M.D., Senior Vice President, Co-Head of Regeneron Genetic Medicines and Head, Regeneron Genetics Center®.

PCP Claims Launches Pioneering No Win, No Fee Service for Victims of Mis-Sold Car Finance

Retrieved on: 
Monday, April 22, 2024
Communication, PCP, Head, Policy

PCP Claims is thrilled to announce the launch of its new service designed exclusively for victims of mis-sold car finance agreements.

Key Points: 
  • PCP Claims is thrilled to announce the launch of its new service designed exclusively for victims of mis-sold car finance agreements.
  • With an established track record spanning over three decades in consumer rights advocacy, PCP Claims brings an unmatched depth of expertise to the mis-sold car finance sector.
  • At PCP Claims, we’ve developed a focused approach to tackle these agreements head-on,” said Steve Jenkins, founder of PCP Claims.
  • “For anyone who feels they have been misled into a car finance agreement, PCP Claims is your advocate, your expert, and your partner in rectifying this wrong,” added Jenkins.

SS Innovations International Announces Q1 2024 Company Updates

Retrieved on: 
Monday, April 22, 2024
Hospital, Neck, OTC, Surgeon, Mantra, Urology, Head, Gynaecology, Dentistry

FORT LAUDERDALE, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced its Q1 2024 Company updates.

Key Points: 
  • FORT LAUDERDALE, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced its Q1 2024 Company updates.
  • As of March 31, 2024, SS Innovations has completed a total of 32 successful installations of the SSi Mantra Surgical Robotic System in medical facilities across India.
  • For the quarter ended March 31, 2024, SS Innovations sold 8 SSi Mantra Surgical Robotic Systems and expects to report revenues of approximately US $7 million, which exceeds revenues reported for the entire year ended December 31, 2023.
  • In addition, SS Innovations also installed a robotic system at the World Laparoscopy Hospital, which is a prominent Minimal Access Surgery Training Institute in India.

Oceana Announces James Simon as New CEO

Retrieved on: 
Friday, April 19, 2024
Harvard Law School, Climate change, McKinsey & Company, Policy, Yale College, Justice, European, Retirement, Culture, Environment, Head, Natural Resources, Criminal defense lawyer, Harvard Law Review, Growth, Management

WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- Oceana’s Board of Directors is pleased to announce it has appointed James (Jim) Simon as the next Chief Executive Officer of Oceana.

Key Points: 
  • WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- Oceana’s Board of Directors is pleased to announce it has appointed James (Jim) Simon as the next Chief Executive Officer of Oceana.
  • This announcement follows an extensive eight-month global search and the upcoming retirement of Andrew Sharpless, Oceana’s longtime CEO.
  • “I’m thrilled and honored to continue working with Oceana’s talented staff and generous supporters in my new role as CEO,” said Jim Simon, Oceana’s longtime President and newly appointed CEO.
  • “The Board undertook an inclusive and fair search process that helped us affirm that Jim Simon is the best person positioned to lead Oceana into the future,” said Oceana Board Member Sara Lowell, who led the CEO search committee.

World Wildlife Fund Launches New PSA to Combat Plastic Pollution featuring U2 song ‘Beautiful Day’

Retrieved on: 
Friday, April 19, 2024
United Nations, Head, Public service announcement, PSA, WWF, Public service, Music, Recycling

The PSA, geared towards addressing the global plastic pollution crisis, features ‘Beautiful Day’ the iconic song by U2, and pairs with a child’s voiceover bringing an unfiltered and hopeful and powerful message to this critical issue.

Key Points: 
  • The PSA, geared towards addressing the global plastic pollution crisis, features ‘Beautiful Day’ the iconic song by U2, and pairs with a child’s voiceover bringing an unfiltered and hopeful and powerful message to this critical issue.
  • In an historic move in 2022, 175 nations voted to adopt a United Nations-led global treaty to end plastic pollution.
  • The Edge, guitarist of U2, stated: We have to wake up to the fact that single use plastic is a biohazard.
  • For more information on WWF's efforts to combat plastic pollution and how people can get involved in supporting the global plastic treaty, please visit wwf.earth/plastics .

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

Retrieved on: 
Thursday, April 18, 2024
Oral medicine, American Academy, Poster, Safety, Radiation, Month, PRO, CFB, Xerostomia, Conference, Treatment, Gene, Head, Parotid gland, Pharmaceutical industry

LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held from April 16-20, 2024, at the Hyatt Regency Grand Cypress in Orlando, FL.

Key Points: 
  • LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held from April 16-20, 2024, at the Hyatt Regency Grand Cypress in Orlando, FL.
  • We assessed the safety and efficacy of AAV2-hAQP1 gene therapy as a treatment for this condition.
  • Twenty-four participants with Grade 2/3 xerostomia at least five years after completing radiotherapy (2 years if HPV+) were enrolled in this multi-center, open-label, dose-escalation study.
  • The presentation will be available on the Posters and Publications page of the Company’s website after the respective presentation session has concluded.

Unispace Group announces new EMEA CEO appointment

Retrieved on: 
Wednesday, April 17, 2024
Overbury, Partner, Selecta, Tydeman, News, Head, Compass Group, Foster and Partners, BPE, PHS, Methodology, PAG, Growth, Management

LONDON, April 17, 2024 (GLOBE NEWSWIRE) -- Unispace Group today announces new London-based hire of Rob Frank as CEO, Corporate Interiors, EMEA and key additions to the growing EMEA leadership team.

Key Points: 
  • LONDON, April 17, 2024 (GLOBE NEWSWIRE) -- Unispace Group today announces new London-based hire of Rob Frank as CEO, Corporate Interiors, EMEA and key additions to the growing EMEA leadership team.
  • Frank will be responsible for the end-to-end delivery of Unispace’s corporate workplace interiors offering for clients across the strategy, design, and construction lifecycle in the EMEA markets.
  • Finally, joining from world-renowned Foster + Partners, Unispace Group has also appointed Charlotte Sword in a global role as Group Chief People Officer.
  • The announcements follow news of Justin Tydeman recently joining as Unispace Group CEO in April, also based in the London studio.

WTW announces appointment of Nick Dussuyer as Head of France and Head of Corporate Risk & Broking France

Retrieved on: 
Tuesday, April 16, 2024
BearingPoint, CRB, Risk, WTW, Strategic management, Specialty, Transformation, Lapeyre, Growth, Head, Specialization

PARIS, April 16, 2024 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking, and solutions company, today announced the appointment of Nick Dussuyer as Head of France and Head of Corporate Risk & Broking (CRB) France.

Key Points: 
  • PARIS, April 16, 2024 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking, and solutions company, today announced the appointment of Nick Dussuyer as Head of France and Head of Corporate Risk & Broking (CRB) France.
  • In addition, Jean Christophe Lapeyre is appointed Head of Specialty & Broking, CRB France and Edouard de Domecy as Head of Regions, CRB France.​
    Anne Pullum, WTW Head of Europe and Head of CRB Europe, commented, “I am delighted that Nick is taking on the role of Head of France and Head of CRB France.
  • Prior to joining WTW, Dussuyer was an equity partner at BearingPoint (previously Arthur Andersen) where he led their client-facing Business Strategy & Transformation team.
  • ​​
    As Head of Specialty & Broking, CRB France, Lapeyre will oversee the global lines of business, broking, and carrier management teams, whilst de Domecy as Head of Regions, CRB France, will oversee the existing regional operations across France.

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

Retrieved on: 
Tuesday, April 16, 2024
Compass, FDA, HNSCC, Hodgkin lymphoma, Doctor of Philosophy, PD-1, IND, PD-L1, Therapy, Patient, Melanoma, Head, NSCLC, TNBC, Lung cancer, Pharmaceutical industry

The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a checkpoint blocker.

Key Points: 
  • The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a checkpoint blocker.
  • CTX-8371 is a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1.
  • Compass advanced CTX-8371 to the clinic following pre-clinical observations of superior activity when compared with approved checkpoint blockers.
  • BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the first patient has been dosed in its Phase 1 dose-escalation clinical trial of CTX-8371, a PD-1 x PD-L1 bispecific antibody, in patients with solid tumors.